As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic ...

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

CAMBRIDGE, Mass., May 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman ...

The US regulator’s decision was supported by results from the phase 3 HELIOS-B trial, in which Alnylam’s drug reduced the ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.

Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $38,973.12 today based on ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 7.7% in that time frame, outperforming the S&P 500. Will the recent positive trend ...